M.E

Digital euro safeguards – protecting financial stability and liquidity in the banking sector

Retrieved on: 
Thursday, April 18, 2024
Central bank, Face, Finance, SUP, HSBC Finance, Digital currency, Frankfurt, Calibration, BIS, Sis, Research Papers in Economics, Excess, Meller, Statistics, PDF, ECB, Blog, Risk, Committee, Learning, Policy, Community business development corporation, Bank, Bank of Canada, Privacy, Social science, Eurosystem, Abstract, Consumption, JEL, SPACE, European Central Bank, Journal, CBDC, Journal of Monetary Economics, Interplay, Private sector, HFCS, Economy, Publication, ISSN, Usher, Conference, Environment, European Parliament, Monetary economics, Household, Reproduction, CEPR, Cournot, LCR, LCRS, M.E

A digital euro would offer a wide range of

Key Points: 
    • A digital euro would offer a wide range of
      financial stability benefits, including safeguarding the role of public money and
      strengthening the strategic autonomy and monetary sovereignty of the euro area in
      the digital era.
    • Keywords: CBDC, digital euro, bank intermediation, financial stability risks.
    • A digital euro has the potential to offer a wide range of financial stability
      benefits for the digital era.
    • A digital euro would
      stimulate financial innovation among private sector entities and enhance the
      efficiency and resilience of the financial system by supporting competition and
      diversity within it.3 In addition, a digital euro would strengthen the strategic autonomy
      and monetary sovereignty of the euro area.
    • A digital euro would be designed to minimise risks to the financial system.
    • 2

      The preparation phase will pave the way for a future decision on whether or not to issue a digital euro.

    • When gauging the implications for the euro area banking sector of introducing a
      digital euro, take-up would be key, as it would determine the level of deposit
      outflows.
    • In the latter case, the
      issuance of a digital euro would not affect banks? balance sheets, since banks would return euro
      banknotes to the Eurosystem in exchange for digital euro.
    • Banknotes and digital euro are two different
      types of central bank liability, so a swap between banknotes and digital euro would only affect the
      composition and not the size of the Eurosystem?s balance sheet.
    • In our analysis, we model only the
      substitution of commercial bank deposits with a possible future digital euro.
    • 8

      The legislative proposal on a digital euro provides for the inclusion of such safeguards and establishes
      specific criteria for the limits, aiming to contain the use of a digital euro as a store of value.

    • ECB Occasional Paper Series No 346

      4

      2

      The added value of digital euro
      safeguards such as holding limits
      To understand the benefits of digital euro safeguards, such as holding limits, it
      is useful to first consider the implications of introducing a CBDC without
      adequate safeguards.

    • (2022), ?Central bank digital currency and bank intermediation: Exploring different
      approaches for assessing the effects of a digital euro on euro area banks?, Occasional Papers, No 293,
      European Central Bank, Frankfurt am Main, May.
    • deciding to adopt the digital euro, and (ii) the average amount of digital euro in a
      wallet.
    • At the same time, as discussed in this paper, the design of a digital euro would
      include effective safeguards, such as individual holding limits, to mitigate
      potential financial stability risks.
    • ECB Occasional Paper Series No 346

      15

      an upper bound on the amount of digital euro in circulation, thereby addressing and
      limiting financial stability concerns associated with the introduction of a digital euro.

    • (2023), ?A digital euro: gauging the
      financial stability implications?, Financial Stability Review, ECB, November.

Solve M.E. Announces Emily Taylor as New President and CEO and Publication of New White Paper Calling for NIH to Restructure Funding for ME/CFS, Long Covid, and other IACCIs

Retrieved on: 
Monday, April 8, 2024
Engagement, STAT, Postural orthostatic tachycardia syndrome, The Washington Post, POTS, Patient, Public, COVID-19, Research, Black, Volunteering, NIH, News, Business News, ScienceDirect, PTLDS, M.E, Management

Emily has been a key member of Solve's leadership team for more than eight years and played a critical role in securing $1.25 billion RECOVER NIH funding for Long Covid research.

Key Points: 
  • Emily has been a key member of Solve's leadership team for more than eight years and played a critical role in securing $1.25 billion RECOVER NIH funding for Long Covid research.
  • Solve Board Chair John Nicols states, "We congratulate Emily and look forward to her leadership."
  • Solve also announces the publication of their newest white paper, co-authored by Emily, " A Home for Infection-Associated Chronic Conditions and Illnesses (IACCIs) at NIH ."
  • BIPOC (Black, Indigenous, and other People of Color), Latino/Latina, LGBTQIA+, and marginalized, underserved and economically disadvantaged populations are disproportionately impacted by IACCIs.

The Benchmark Company Expands its Technology M&A Focus with Leadership Hires

Retrieved on: 
Thursday, October 12, 2023
Benchmark, Cloud, Data infrastructure, Mobility, Corporation, Investment banking, TMT, William Blair & Company, University, Digital media, Lehman Brothers, Rensselaer Polytechnic Institute, Enterprise, AudioCodes, Amherst College, Growth, Cornell University, United Nations Technology Bank for Least Developed Countries, Customer engagement, Cloud communications, M.E, Research, Cryptocurrency, Financial services, Computer security, Telecom

Derek Wittenberg and Dmitry Netis , both Managing Directors, Investment Banking, are establishing and leading the firm’s Technology, Media, and Telecom (TMT) M&A vertical.

Key Points: 
  • Derek Wittenberg and Dmitry Netis , both Managing Directors, Investment Banking, are establishing and leading the firm’s Technology, Media, and Telecom (TMT) M&A vertical.
  • "Technology is reshaping all of our clients' industries and represents a significant opportunity for their differentiation and growth.
  • “We are excited to join the Benchmark banking team to strengthen the firm’s investment banking focus in this important sector.
  • We look forward to Derek and Dmitry’s contributions to our deep bench of banking and advisory professionals,” added Richard Messina.

Quincy, M.E. Coming to FETV August 28th

Retrieved on: 
Wednesday, August 9, 2023
Season, FETV, Drama, Emergency, Television, NBC, Film industry, M.E, Nielsen

SOUTH BEND, Ind., Aug. 9, 2023 /PRNewswire/ -- FETV (Family Entertainment Television), home to beloved and timeless television series and movies carried across cable, satellite, and virtual platforms, announced today that Quincy, M.E. will join the network's programming lineup beginning Monday, August 28th. The show will debut in its regular time slot every night at 7p ET, leading into Perry Mason at 8p ET.

Key Points: 
  • will join the network's programming lineup beginning Monday, August 28th.
  • The show will debut in its regular time slot every night at 7p ET, leading into Perry Mason at 8p ET.
  • to the FETV lineup," said Jaclyn Rann Cohen, Executive Vice President, Content Acquisitions & Strategy.
  • FETV's current lineup features popular television series such as Emergency!, Leave It to Beaver, Perry Mason, and Adam-12.

FzioMed Announces Addition of Industry Veteran to its Board of Directors

Retrieved on: 
Thursday, May 18, 2023
University, Elective surgery, Spine, University of California, MBA, Case Western Reserve University, Research, Biomedical engineering, M.E, Patient, Physician, SAN, General surgery, Johnson & Johnson, Health, FDA, Therapy, University of Virginia, Nursing

SAN LUIS OBISPO, Calif., May 17, 2023 /PRNewswire/ -- FzioMed, Inc. ("FzioMed" or the "Company"), a global leading surgical biomaterials company focused on spine, orthopedic, peritoneal and gynecological surgery, today announced the appointment of industry veteran Alex DiNello to its Board of Directors whose appointment became effective May 1, 2023.

Key Points: 
  • SAN LUIS OBISPO, Calif., May 17, 2023 /PRNewswire/ -- FzioMed, Inc. ("FzioMed" or the "Company"), a global leading surgical biomaterials company focused on spine, orthopedic, peritoneal and gynecological surgery, today announced the appointment of industry veteran Alex DiNello to its Board of Directors whose appointment became effective May 1, 2023.
  • "I am very excited to welcome Alex to FzioMed.
  • His vast knowledge and experience in healthcare will be a valued addition to our Company," said Paul Mraz, President and CEO of FzioMed.
  • Alex currently serves as President and CEO of Sollis Therapeutics, a clinical-stage interventional pain therapy company.

Tonix Pharmaceuticals Describes Emerging Research on the Incidence of Multi-Site Pain Symptoms in Long COVID Patients During Event Titled, “Long COVID: What Will it Take to Accelerate Therapeutic Progress?”

Retrieved on: 
Wednesday, February 22, 2023
United States Department of Health and Human Services, CFS/ME, SL, Advocacy group, Chronic pain, Biotechnology Innovation Organization, Assistant, Research, Acceleration, Patient, M.E, Office of the Assistant Secretary for Health, BIO, Tonix Pharmaceuticals, Infection, CFS, Fatigue, Fibromyalgia, Insomnia, COVID, Pharmaceutical industry, Health, Long COVID

CHATHAM, N.J., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that during a virtual event co-hosted by BIO and Solve M.E. titled, “Long COVID: What Will it Take to Accelerate Therapeutic Progress?”, Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals, presented emerging research describing the role of infections in triggering fibromyalgia or CFS/ME and other fibromyalgia-type illnesses, and discussed Tonix’s ongoing Phase 2 study of TNX-102 SL in fibromyalgia-type Long COVID. Symptoms of Long COVID, like multi-site pain, fatigue and insomnia, are the hallmarks of chronic pain syndromes like fibromyalgia and CFS/ME.

Key Points: 
  • Symptoms of Long COVID, like multi-site pain, fatigue and insomnia, are the hallmarks of chronic pain syndromes like fibromyalgia and CFS/ME.
  • “Furthermore, a recent survey2 found comparable pain, fatigue and function between Long COVID, fibromyalgia and CFS/ME.”
    Enrollment continues in the Phase 2 PREVAIL study of TNX-102 SL as a potential treatment for patients with Long COVID syndrome whose symptoms overlap with fibromyalgia.
  • PREVAIL is a randomized, double-blind, placebo-controlled study in the U.S. that is expected to enroll approximately 470 patients.
  • National Research Action Plan on Long COVID, 200 Independence Ave SW, Washington, DC 20201.

AIM ImmunoTech to Participate in Solve M.E. and The Biotechnology Innovation Organization (BIO) Virtual Event, “Long Covid: What Will It Take To Accelerate Therapeutic Progress?”

Retrieved on: 
Friday, February 17, 2023
Fatigue, Viral, Experiment (probability theory), Government, BIO, Acceleration, Therapy, AIM, Cancer, NYSE, Biotechnology Innovation Organization, Patient, Microsoft Access, Research, DSM-IV codes, Immune system, Disease, FDA, ME/CFS, COVID-19, M.E, Pharmaceutical industry, Long COVID, Rintatolimod

Diagnostics and The Biotechnology Innovation Organization (BIO) titled, “ Long Covid: What Will It Take To Accelerate Therapeutic Progress?

Key Points: 
  • Diagnostics and The Biotechnology Innovation Organization (BIO) titled, “ Long Covid: What Will It Take To Accelerate Therapeutic Progress?
  • ,” being held virtually on Tuesday, February 21, 2023, from 10:00 AM – 1:00 PM PT.
  • The goal of the virtual event is to convene stakeholders to advance research and development to diagnose and treat Long Covid, ME/CFS, and post-infection diseases.
  • By increasing awareness among drug developers to the unmet needs of our communities, Solve M.E.

Axcella Announces FDA IND Clearance Supporting Regulatory Path to Registration of AXA1125 for Long COVID Fatigue

Retrieved on: 
Wednesday, February 15, 2023
Health, FDA, COVID-19, Clinical Trials, Pharmaceutical, Biotechnology, Fatigue, Medication, Government, BIO, SOLVE, Randomized controlled trial, Biotechnology Innovation Organization, MHRA, Safety, Patient, Webcast, Food, Research, Therapy, EMM, Policy, Health care, Disease, ME/CFS, COVID, Beth Israel Deaconess Medical Center, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Quality of life, M.E, IND, Pharmaceutical industry, Long COVID

The company reported that it had received regulatory guidance from the FDA, supporting a trial that is designed to serve as the registration trial for patients with Long COVID Fatigue.

Key Points: 
  • The company reported that it had received regulatory guidance from the FDA, supporting a trial that is designed to serve as the registration trial for patients with Long COVID Fatigue.
  • Last month, the company announced a regulatory path to registration of AXA1125 in the treatment of Long COVID Fatigue, and that it had received regulatory guidance from The Medicines and Healthcare products Regulatory Agency (MHRA), the U.K.’s regulatory agency, supporting a single trial that could serve as the registration trial for patients with Long COVID Fatigue.
  • There are millions of people around the world suffering from Long COVID Fatigue who are without options.
  • Axcella will make a presentation at the forum to discuss its novel approach to treating Long COVID Fatigue and its promising clinical data.

Solve M.E. Awarded Grant From Chan Zuckerberg Initiative to Support Patient Engagement in Long Covid Research

Retrieved on: 
Tuesday, December 13, 2022
PASC, Trust, Publication, COVID-19, COVID-19 policy of the Joe Biden administration, Food, Survivor, Human, Government, Chan Zuckerberg Initiative, Research, Patient, Curriculum, Myalgia, Solve, Knowledge, Disease, FDA, Drug development, Caregiver, Education, CZI, Food and Drug Administration Amendments Act of 2007, ME/CFS, M.E, Solve ME/CFS Initiative, Pharmaceutical industry, Long COVID, Science

LOS ANGELES, Dec. 13, 2022 /PRNewswire/ -- Today, Solve M.E. announced it is the recipient of significant grant funding from the Chan Zuckerberg Initiative (CZI). With the $247,500 in funding, Solve M.E. will develop a groundbreaking program that will train a network of patient leaders, scientists and other stakeholders with diverse backgrounds to enhance patient engagement in Long Covid research. These trained patient representatives will ultimately create a targeted research agenda, a network of empowered patient-advocates and a guide to working with Long Covid patients for researchers. These critical tools will provide urgently needed guidance on achieving patient-centered research in the Long Covid field, as well as help to empower communities in other related fields.

Key Points: 
  • will develop a groundbreaking program that will train a network of patient leaders, scientists and other stakeholders with diverse backgrounds to enhance patient engagement in Long Covid research.
  • These trained patient representatives will ultimately create a targeted research agenda, a network of empowered patient-advocates and a guide to working with Long Covid patients for researchers.
  • In key publications, like the National Research Action Plan on Long Covid 3and the recent Health+ Long Covid report 4, patient contributions have been vital.
  • to solve Long Covid and associated conditions, as well as participating in research and joining in advocacy and awareness efforts.

AIM ImmunoTech Announces FDA Clearance of IND Application to Evaluate Ampligen® in Phase 2 Clinical Study for the Treatment of Post-COVID Conditions

Retrieved on: 
Wednesday, October 12, 2022
Method, Lists of diseases, Physician, Solve ME/CFS Initiative, American, Disease, Therapy, PSLRA, Fatigue, IND, NYSE, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, Research, Solve, AIM, Parallel Walk Test, Long, Knowledge, Private Securities Litigation Reform Act, Food, Immune system, Trial of the century, Company, Doctor of Philosophy, Myalgia, Degenerative disease, CEO, Patent, Safety, GLOBE, PLOS, Clinical trial, Government, Running, FDA, COVID-19, ME/CFS, Cancer, M.E, Pharmaceutical industry, Long COVID, Rintatolimod

AIM has pending patent applications for compositions and methods for treating post-COVID conditions with a composition comprising Ampligen.

Key Points: 
  • AIM has pending patent applications for compositions and methods for treating post-COVID conditions with a composition comprising Ampligen.
  • Post-COVID-19 Disabling Fatigue, along with other debilitating post-COVID conditions such as Brain Fog, continue to affect tens of millions of people worldwide.
  • The planned Phase 2 study is a two-arm, randomized, double-blind, placebo-controlled, multicenter study to evaluate efficacy and safety of Ampligen in patients experiencing the post-COVID condition of fatigue.
  • Significant additional testing and trials will be required to determine whether Ampligen will be an effective treatment for Long COVID.